Skip to content
Menu

Arcturus Therapeutics Holdings Inc. ARCT

Full chart Compare
Set alert

Price alert · ARCT

All alert types
7.45 USD -0.15 (-1.97%)

Regular-session close

7.45 0.00 0.00%

After hours · Nov 20, 4:01 PM ET

7.31 Day range 7.73
5.50 52-week range 17.96
YTD
+21.53%
1 year
+26.27%

5D -1.55 (-16.28%)

89WedThuFriMonTue7.97
Market cap
214.73M
Revenue (ttm)
160.40M
Profit margin
-39.05%
EPS (ttm)
-3.10
Shares out
27.09M
Forward P/E
-7.41
YTD return
+21.53%
1-year return
+26.27%
50-day average
18.22
Volume
591.58K
Avg volume
886.59K
Open
7.38
Previous close
7.60
Day's range
7.31 – 7.73
52-week range
5.50 – 17.96
Beta
2.64
Analysts
Strong Buy
Price target
79.47 (+966.7%)

Key statistics

200-day average
24.44
Enterprise value
211.56M
Price / sales
2.79
Price / book
1.71
Revenue growth
-7.70%
Free cash flow
-40.26M
Total cash
237.18M
Total debt
29.42M
Return on equity
-23.12%
Short % of float
25.29%

Fundamental scorecard

6 of 25 checks passed on ARCT’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ARCT Revenue — quarterly 18.30M
ARCT Net income — quarterly -7.41M
ARCT EPS — quarterly -0.26

Earnings

ARCT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.70-0.26+0.44+62.86%
Aug 5, 2024Jun 1, 2024-1.85-0.64+1.21+65.41%
May 8, 2024Mar 1, 2024-1.17-1.00+0.17+14.53%
Mar 7, 2024Dec 1, 2023-1.69-0.32+1.37+81.07%
Nov 14, 2023Sep 1, 2023-1.79-0.61+1.18+65.92%
Aug 7, 2023Jun 1, 20230.09-1.98-2.07-2,300.00%

Upgrades / downgrades

ARCT analyst upgrades and downgrades
DateFirmActionFromTo
Dec 17, 2024HC Wainwright & Co.reitBuyBuy
Dec 16, 2024Cantor FitzgeraldreitOverweightOverweight
Nov 8, 2024HC Wainwright & Co.reitBuyBuy
Aug 12, 2024Leerink Partnersinit—Outperform
Aug 8, 2024HC Wainwright & Co.mainBuyBuy
Aug 6, 2024Cantor Fitzgeraldreit—Overweight

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ARCT — it syncs with the Stock Master app.

Insider holders

ARCT insider holders
InsiderRelationLatest transactionDateShares held
BARLOW JAMES F.DirectorConversion of Exercise of derivative securityJun 13, 202413,131
CHIVUKULA PADMANABHChief Operating OfficerSaleOct 14, 2024435,334
FARRELL PETER CRAIGDirectorConversion of Exercise of derivative securityJun 13, 202498,696
HOLMES EDWARD W.DirectorConversion of Exercise of derivative securityJun 13, 20243,131
KUMMERFELD KEITH COfficerSaleJul 13, 2023950
MARANTZ JING L.DirectorConversion of Exercise of derivative securityJun 13, 20243,131

Institution ownership

ARCT institution ownership
Holder% heldSharesValueReported
Federated Hermes, Inc.17.33%4,694,06077.59MSep 29, 2024
Blackrock Inc.10.90%2,952,01348.80MSep 29, 2024
Nikko Asset Management Americas, Inc.8.55%2,315,29438.27MSep 29, 2024
Sumitomo Mitsui Trust Holdings, Inc.8.40%2,275,71537.62MSep 29, 2024
ARK Investment Management, LLC7.76%2,101,03834.73MSep 29, 2024
Vanguard Group Inc5.82%1,576,92626.07MSep 29, 2024

Fund ownership

ARCT fund ownership
Holder% heldSharesValueReported
Federated Hermes Kaufmann Fund8.99%2,435,88040.27MJul 30, 2024
Federated Hermes Kaufmann Small Cap Fund8.11%2,198,02036.33MJul 30, 2024
ARK ETF Tr-ARK Genomic Revolution ETF7.53%2,038,67533.70MOct 30, 2024
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF2.77%749,64412.39MSep 29, 2024
Vanguard Total Stock Market Index Fund2.67%723,64011.96MSep 29, 2024
iShares Russell 2000 ETF2.19%593,7819.82MOct 30, 2024